Swiss open to compromise in Covid vaccine talks at WTO
Switzerland remains opposed to a full waiver of the intellectual property rights of Covid-19 vaccines and drugs
Keystone / Peter Schneider
Switzerland is open to compromise in talks on the intellectual property (IP) rights of Covid-19 vaccines and drugs at the World Trade Organization (WTO), but it remains opposed to a full waiver of those rights, says a senior Swiss diplomat.
This content was published on
2 minutes
Reuters/ts
Switzerland is one of a handful of WTO members alongside Britain and the European Union opposed to a waiver of IP rights protected by the TRIPS agreement in negotiations at the WTO that began in October 2020.
Proponents and activists are heaping pressure on those hold-out countries ahead of a ministerial conference in Geneva next week and plan to stage protests.
“We remain convinced that the TRIPS waiver will not result in one additional dose of vaccine and may jeopardise existing partnerships that have allowed us to increase production,” Didier Chambovey, Switzerland’s ambassador to the WTO, told reporters on Thursday.
However, he said the Swiss view was not “totally rigid” and that the country was in discussions with others about potentially finding agreement, without giving details of those discussions.
“We are really ready to look into this and to make a step in the direction of the other side,” Chambovey said.
Areas of compromise might involve simplifying the processes for compulsory licences and improving technology transfers, he said.
More
More
Swiss not swayed by US vaccine waiver announcement
This content was published on
Switzerland will “evaluate” the new proposition, but “many questions remain open”, the economics ministry said.
Activists say a waiver would help address vaccine inequity, noting that fewer than 7% of people in low-income countries had received a first Covid-19 shot and that supplies remained scarce.
Chambovey described this as a “real challenge” but said that removing patent protection would not solve this. He said difficulties with distribution, unfulfilled dose pledges, vaccine hoarding and poor health infrastructure in developing countries were to blame.
In his view, a more effective route is to use existing flexibilities in the TRIPS agreement that allow governments to issue “compulsory licences” to manufacturers.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
What can be done to protect biodiversity in your country?
Swiss voters are set to decide on a people’s initiative calling for better protection of ecosystems in the country. Have your say on the September 22 vote.
Swiss investigate four people linked to Russian oligarch
This content was published on
The Office of the Attorney General of Switzerland is investigating four individuals linked to Russian oligarch Suleyman Kerimov.
Swiss government scrambles to deal with egg shortage
This content was published on
From September 1, more eggs intended for consumption may be imported into Switzerland. In allowing this, the government wants to secure the supply of eggs for consumers.
This content was published on
Agricultural research sees new development opportunities for Swiss sparkling wines in the face of declining wine consumption. In a survey, half of consumers expressed a willingness to pay more for local products than for foreign ones.
Locarno spotlights filmmakers from South America and Caribbean
This content was published on
The Open Doors section of the Locarno Film Festival has named the winners for 2024. The spotlight is on the South American and Caribbean regions.
Storm paralyses trains to popular Swiss tourist resort
This content was published on
The railway line between Zweilütschinen and Grindelwald in central Switzerland is expected to remain closed until Friday following heavy rains.
Calls intensify for Big Pharma to break monopolies on Covid-19 vaccines
This content was published on
Pressure is mounting to suspend intellectual property rules to help vaccines reach more people. Can the WTO find a solution?
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.